8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
1/21
2246
Ahigher level of serum low-density lipoprotein choles-terol (LDL-C) is a major risk factor for atherosclerosis,which is a cause of cardiovascular disease. Several clinical
trials have demonstrated that cholesterol-lowering therapy
with statin reduces the risk of cardiovascular events.1,2 On
the contrary, a lower level of serum high-density lipoprotein
cholesterol (HDL-C) is considered to be independently and
inversely associated with the risk of cardiovascular disease,3
and in addition to a lower LDL-C level, an increase in HDL-C
has been suggested to be a secondary lipid target for reducing
the risk of cardiovascular disease.4
Even in patients who aretreated aggressively with statins to reduce LDL-C levels
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
2/21
Shimizu et al Rosuvastatin Promotes RCT 2247
important roles. Second, HDL-C is transported in blood to the
liver, and the cholesterol in HDL is converted to cholesteryl
ester (CE) by the enzyme lecithin-cholesterol acyltransferase
(LCAT) and carried as CE in the core of the HDL particle to
the liver. Finally, CE is excreted from the liver into bile, either
directly or after conversion to bile acids.
Atorvastatin and rosuvastatin are well known to be the most
effective statins for lowering LDL-C levels. Several clinical
trials have reported that aggressive lipid-lowering therapy not
only suppresses the progression of atherosclerosis, but also
contributes to its regression.9–11 Although the administration of
rosuvastatin and atorvastatin resulted in a significant regres-
sion of coronary atherosclerosis12 and significantly increased
HDL-C levels,12–16 the effects of statins on the 3 stages of RCT
in vivo have not yet been reported. We hypothesized that these
strong statins might promote the expression of several factors
involved in RCT independent of lowering LDL-C, and there
might be differences in the effects of rosuvastatin and atorv-
astatin on RCT. Therefore, the aim of the present study was to
clarify the effects of rosuvastatin and atorvastatin in an in vivomacrophage RCT system and their underlying mechanisms.
Materials and MethodsMaterials and Methods are available in the online-only Supplement.
Results
Rosuvastatin and Atorvastatin Prevented theIncrease in Triglyceride Without Changesin HDL-C, LDL-C, or non–HDL-C
Changes in the lipid profile before and after 6 weeks of statin
administration are shown in the Table. The control group
did not show significant changes in plasma total cholesterol,
LDL-C, or non–HDL-C levels before and after 6 weeks. Both
the rosuvastatin and atorvastatin groups also did not show
changes of the levels before and after treatment. In addition,
there were no significant changes in the levels of HDL-C in
all 3 groups before and after 6 weeks. However, there were
significant changes in plasma triglyceride levels after treat-
ment. There was a significant increase in the triglyceride level
at 6 weeks in the control group, whereas neither rosuvastatin
nor atorvastatin changed the triglyceride level, indicating that
statins prevented the increase in the triglyceride level at 6
weeks.
Rosuvastatin, but Not Atorvastatin, IncreasedPre-β HDL Without Decreasing LCAT ActivityNext, we analyzed HDL subfractions as assessed by capil-
lary isotachophoresis on a Beckman P/ACE MDQ system
(Beckman-Coulter, Tokyo, Japan) as described previously,17
as shown in Figure 1A and 1B. Capillary isotachophoresis is
a technique for analyzing charge-based lipoprotein subfrac-tions directly in plasma.18,19 Capillary isotachophoresis can
separate plasma lipoproteins into 3 HDL subfractions (fast-,
intermediate-, and slow-migrating HDL) according to their
electrophoretic mobilities. The rosuvastatin group, but not the
atorvastatin and control groups, showed a significant increase
in pre-β HDL, which indicates peaks in slow-migrating HDL,
after administration. The absolute amounts of slow-migrating
HDL in each group were analyzed at weeks 0 and 6. There
were no significant differences among the 3 groups at week
0. At 6 weeks, the rosuvastatin group showed a significant
increase in the percentage of the slow-migrating HDL fraction
compared with the atorvastatin and control groups. Because
plasma LCAT is critical for HDL maturation, we analyzed
whether these changes were influenced by LCAT activity
(Figure 1C). There were no differences in the activity of LCAT
between the groups, indicating that rosuvastatin increased pre-
β HDL without decreasing LCAT activity.
Rosuvastatin, but Not Atorvastatin, DecreasedmRNA Levels of Apolipoprotein A-I in the liverWe isolated the livers from mice in the rosuvastatin, atorv-
astatin, and control groups at 6 weeks and analyzed mRNA
expression levels of various factors (Figure 2). Rosuvastatin and
atorvastatin had no significant effects on mRNA levels of SR-BI
Nonstandard Abbreviations and Acronyms
ABC ATP-binding cassette transporter
ApoA-I apolipoprotein A-I
CE cholesteryl ester
HDL high-density lipoprotein
HDL-C high-density lipoprotein cholesterolLCAT lecithin-cholesterol acyltransferase
LDL-C low-density lipoprotein cholesterol
RCT reverse cholesterol transport
SR-BI scavenger receptor class B type I
Table 1. Lipid Profile in Rosuvastatin, Atorvastatin, and Control Groups at 0 and 6 Weeks
Group Weeks TC, mg/dL HDL-C, mg/dL LDL-C, mg/dL Triglyceride, mg/dL Non–HDL-C, mg/dL
Rosuvastatin (n=8) 0 95±12 51±16 41±10 21±8 45±9
6 86±20 44±10 46±14 21±10* 42±22
Atorvastatin (n=8) 0 95±12 51±14 40±11 23±7 45±12
6 93±11 43±9 45±7 30±8* 50±8
Control (n=7) 0 99±14 51±15 43±11 24±11 48±8
6 101±14 50±15 42±10 45±11† 51±10
HDL-C indicates high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; and TC, total cholesterol.
*P
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
3/21
2248 Arterioscler Thromb Vasc Biol October 2014
and ABCA1 (Figure 2A and 2B). The mRNA levels of liver
X receptor, farnesoid X receptor, apolipoprotein A-I (ApoA-I),
and ABCG8 in the liver in the rosuvastatin group were signifi-
cantly lower than those in the control group (Figure 2C–2F).
The atorvastatin group also showed a significant reduction in
liver X receptor mRNA expression compared with the control
group (Figure 2C). Furthermore, ApoA-I mRNA expression
in the rosuvastatin group was significantly less than that in the
atorvastatin group (Figure 2E). On the contrary, there were no
significant differences in ABCG5 or sterol regulatory element-
binding protein 2 among the 3 groups (Figure 2G and 2H).
Rosuvastatin, but Not Atorvastatin, IncreasedCholesterol Efflux via ABCA1 Ex Vivo
We examined whether cholesterol efflux via the ABCA1pathway was enhanced by rosuvastatin, because rosuvastatin
increased pre-β HDL after treatment. Pooled plasma from mice
that had been treated with rosuvastatin, atorvastatin, or placebo
for 6 weeks was used for ex vivo cholesterol efflux studies
with bone marrow macrophage from mice and J774 macro-
phages. Before the experiments, apolipoprotein B–containing
protein was excluded from pooled plasma. For the preparation
of apolipoprotein B–depleted plasma, plasma was mixed with
phosphotungstic acid and magnesium chloride. As shown
in Figure 3A to 3C, we measured plasma HDL-C–mediated
efflux in bone marrow macrophage with or without probucol,
which specifically inhibits ABCA1. Plasma from the rosuvas-
tatin group had significantly greater cellular cholesterol effluxcapacity than plasma from the atorvastatin and control groups
(Figure 3A). However, no significant difference was seen with
the use of probucol (Figure 3B). In addition, plasma from the
rosuvastatin group had a significantly greater capacity to pro-
mote ABCA1-specific efflux than plasma from the atorvastatin
and control groups (Figure 3C). Similar results were observed
regarding cholesterol efflux using J774 cells. The rosuvastatin
group had significantly greater total efflux than the atorvas-
tatin and control groups (Figure 3D). In addition, with J774
cells in which ABCA1 was stimulated by 3′-5′-cAMP, total
efflux in the rosuvastatin group was significantly greater than
those in the atorvastatin and control groups (Figure 3E).
Rosuvastatin, but Not Atorvastatin,Promoted Macrophage RCT In VivoWe investigated the differences in the effects of rosuvastatin
and atorvastatin on RCT in macrophage cells. As shown in
Figure 4A, after 3H-cholesterol–labeled J774 cells were injected
into the peritoneal cavity of mice, the 3H-cholesterol counts in
plasma (3H-plasma) were determined and expressed as a per-
centage of the total label injected (percentage of injection).
There was no difference in the percentage of injection at each
time point between the atorvastatin and control groups, whereas3H-plasma in the rosuvastatin group was significantly greater at
all time points compared with those in the atorvastatin and controlgroups. However, there was no difference in 3H-Liver between
the rosuvastatin and atorvastatin groups (Figure 4B). Although
there was no difference in 3H-Liver between the rosuvastatin
and control groups, 3H-Liver in the atorvastatin group was sig-
nificantly lower than that in the control group. Furthermore, the
rosuvastatin group had significantly higher 3H-cholesterol levels
in 3H-Feces than the atorvastatin and control groups (Figure 4C).
Rosuvastatin, but Not Atorvastatin,Increased Cholesterol Excretion From theLiver Without Increasing Turnover
Finally, we investigated the effects of statins on the turn-over and fecal excretion of HDL-derived cholesterol. Plasma
LCAT
rosuvastatin atorvastatin control
0
100
200
300
400
A c t i v i t y ( n m o l / m
l / h r )
C
B
A
Figure 1. A , Lipoprotein subfractions as assessed by capillaryisotachophoresis (cITP) in plasma taken from wild-type (WT)mice before and after the administration of statins. The cITPtechnique separates plasma lipoproteins into 3 high-densitylipoprotein (HDL) subfractions (fast-, intermediate-, and slow-migrating HDL [fHDL, iHDL, and sHDL]) according to their elec-trophoretic mobilities. Dotted squares indicate pre-β HDL whichshows peak in sHDL. B, Absolute amount of sHDL as pre-β HDL
in plasma taken from WT mice before (week 0) and after (week6) the administration of statins. The levels of cITP HDL subfrac-tions can be determined as peak areas relative to that of aninternal marker. *P
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
4/21
Shimizu et al Rosuvastatin Promotes RCT 2249
3H-cholesteryl oleate-loaded HDL was decreased equally in
all 3 groups (Figure 5A), consistent with the results regarding
fractional catabolic rate (Figure 5B). On the contrary, there
were differences in fecal excretion. The rosuvastatin group
showed a significant increase in 3H-cholesterol in feces com-
pared with the atorvastatin and control groups (Figure 5C).
Interestingly, the rosuvastatin group showed a significant
increase in the fecal excretion of 3H-free-cholesterol, but not3H-bile acids (Figure 5D and 5E). These results indicate that
rosuvastatin, but not atorvastatin, enhanced the excretion of
HDL-derived cholesterol into feces and support the findingthat rosuvastatin promoted RCT in macrophage cells. This
is consistent with the notion that rosuvastatin increases the
excretion of cholesterol from the liver.
DiscussionIn the present study, rosuvastatin, but not atorvastatin,
increased macrophage-to-HDL RCT by activating cholesterol
efflux via ABCA1. Furthermore, rosuvastatin increased liver-
to-feces RCT by promoting the fecal excretion of HDL-derived
cholesterol. This difference in the effects of rosuvastatin and
atorvastatin may promote the regression of atherosclerosis.
We clarified the differences in RCT in vivo between treat-ment with rosuvastatin and atorvastatin in mice. There are 3
key steps in RCT: cholesterol efflux from macrophage cells
to plasma HDL acceptors, uptake from plasma to the liver
by HDL-C, and HDL-derived cholesterol excretion from the
liver to bile. In the overall mechanism of RCT, rosuvastatin
activates both the extraction of cholesterol from peripheral
macrophage cells and the excretion of cholesterol from the
liver into feces or bile. Rosuvastatin increased both choles-
terol efflux via ABCA1 ex vivo and cholesterol excretion from
the liver without increasing turnover. These results suggest a
mechanism for the regression of atherosclerosis independent
of lowering LDL-C and have implications for our understand-ing of the effects of rosuvastatin on RCT.
With regard to the mechanism by which rosuvastatin activates
RCT, not only it can activate cholesterol efflux from peripheral
macrophage cells, but it can also increase the excretion of cho-
lesterol into feces. As the same conditions as the occasion where
cholesterol efflux from a peripheral macrophage is equivalent
(turnover study; Figure 5), we observed cholesterol excretion
into feces after the intravenous injection of HDL containing an
equivalent amount of cholesterol. As a result, cholesterol excre-
tion into feces was increased as in the RCT study (Figure 4). If
cholesterol transfer to the liver by HDL is increased, cholesterol
excretion into feces would also be increased. Unexpectedly, there
were no differences in cholesterol transfer to the liver by HDL
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
SR-B1 mRNA expression
(AU)
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
2.0
LXR mRNA expression
* *
(AU)
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
ABCA1 mRNA expression
(AU)
A B C
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5 FXR mRNA expression
*(AU)
D
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
ABCG8 mRNA expression
*(AU)
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5Apo A-1 mRNA expression
**(AU)
E F
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
ABCG5 mRNA expression
(AU)
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
2.0
SREBP-2 mRNA expression
(AU)
G H
Figure 2. Effects of statins on mRNA expression levels of various factors in mouse hepatocytes (n=7 in each group). Scavenger receptorclass B type I (SR-BI; A ), ATP-binding cassette transporter A1 (ABCA1; B ), liver X receptor (LXR; C ), farnesoid X receptor (FXR; D ), apo-lipoprotein A-I (ApoA-I; E ) ABCG8 ( F ), ABCG5 ( G ), and sterol regulatory element-binding protein 2 (SREBP-2; H ). *P
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
5/21
2250 Arterioscler Thromb Vasc Biol October 2014
between the groups after the intravenous injection of 3H-labeled
cholesteryl-loaded HDL, which indicated that rosuvastatin did
not influence the transfer of HDL from peripheral tissue to the
liver (Figure 5). Although cholesterol in feces was increased
(Figure 4), there were no differences in the attenuation of choles-
terol in blood after intravenous injection. This observation was
important. Specifically, rosuvastatin did not alter blood choles-terol levels. Cholesterol that is transported to the liver might be
excreted into bile as free cholesterol, without being metabolized
to bile acid. Thus, it is not possible to obtain a final conclusion
from these results.
Recently, Le May et al20 reported that transintestinal choles-
terol excretion is an important pathway for hepatobiliary secre-
tion by statin. Little is known about the effects of statins on the
intestine. Transporters, ABCG5/8 and ABCB1a, in addition
to Niemann-Pick C1-Like 1 and LDL receptor, significantly
contribute to transintestinal cholesterol excretion. Although
we analyzed mRNA levels of ABCG5, ABCB1a, Niemann-
Pick C1-Like 1, and LDL receptor in the intestine after statin
treatment (Figure I in the online-only Data Supplement), there
were no significant changes in the levels of these mRNAs. In
addition, we also examined whether statins effect an intestinal
absorption of cholesterol. Although we performed an addi-tional experiment, there was no difference in the intestinal
absorption of cholesterol between rosuvastatin and atorvas-
tatin (Figure II in the online-only Data Supplement). We could
not explain transintestinal cholesterol excretion with respect
to the mechanism of the differential effects of RCT between
rosuvastatin and atorvastatin.
There are several clinical reports that the administration of
statins increases HDL-C.13–16 Unlike these clinical results, a
significant increase in plasma HDL-C was not seen after the
3H-Plasma
0 10 20 30 40 50
0
2
4
6
8
A B C
rosuvastatin
atorvastatin
control
*
* *
Time(hrs)
% o
f i n j e c t i o n / m l
rosuvastatin atorvastatin control
0
1
2
3
4
3H-Liver
% C
P M i
n j e c t e d
*
3H-Feces
rosuvastatin atorvastatin control
0
2
4
6
**
% C
P M
i n j e c t e d
Figure 4. Effects of statins on reverse cholesterol transport (RCT) in mice. C57BL6 (wild type) mice were fed a high-cholesterol diet for 2weeks and then divided into rosuvastatin, atorvastatin, and placebo control groups (n=7 each). The respective drugs were administeredorally for 6 weeks, and RCT was studied as described in the Materials and Methods in the online-only Data Supplement. 3H-cholesterol
in plasma after macrophage injection ( A ),3
H-cholesterol in the liver ( B ), and3
H-cholesterol in feces ( C ). CPM indicates counts per minute.*P
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
6/21
Shimizu et al Rosuvastatin Promotes RCT 2251
administration of statins. A lack of cholesterol ester transfer
protein in mice might be one of the reasons for this result.
In addition, Tamehiro et al21 reported that the dual promoter
system driven by sterol regulatory element-binding protein 2
and liver X receptor, respectively, regulates hepatic and extra-
hepatic ABCA1 expression. The increase in HDL-C levels
by statins in humans may be partly attributable to increasedliver-specific transcripts as a result of the activation of a liver-
type promoter. In the present study, statins did not increase
the mRNA levels of sterol regulatory element-binding protein
2 or liver X receptor in the liver. Fortunately, there were no
significant differences in HDL-C concentrations among the 3
groups, and we could perform further experiments to analyze
the mechanisms by which rosuvastatin enhanced RCT inde-
pendent of plasma HDL-C levels. Although rosuvastatin did
not change HDL-C levels compared with those in the other
groups, cholesterol efflux was enhanced via ABCA1. We
considered that rosuvastatin altered the HDL composition
and analyzed this composition by capillary isotachophoresis.
Rosuvastatin significantly increased the pre-β HDL fraction,which has higher cholesterol efflux capacity. Recently, an
exciting new therapeutic strategy that uses cholesterol ester
transfer protein inhibitors has gained attention.22–24 Cholesterol
ester transfer protein inhibitors markedly increase HDL-C and
decrease LDL-C when administered as monotherapy or when
administered in combination with statins. Based on the results
of the present study, the combination of cholesterol ester trans-
fer protein inhibitors with rosuvastatin may promote RCT via
the induction of pre-β HDL.
LCAT is critical for the maturation and maintenance of nor-
mal HDL metabolism. Hydrophobic CE by LCAT moves to the
core of HDL particles, where it contributes to the generationof mature HDL particles and their progressive enlargement.
Glomset25 proposed that LCAT plays a central role in RCT by
removing free cholesterol from the surface of HDL, thus help-
ing to maintain a gradient of free cholesterol from cells to HDL.
We considered that rosuvastatin reduces LCAT activity and
increases the nascent HDL component. The effects of statins
on LCAT activity are controversial. For example, the adminis-
tration of rosuvastatin in rats did not change LCAT activity. 26 Conversely, when mice were administered simvastatin or when
humans were administered atorvastatin or pravastatin, LCAT
activities increased.14,27,28 In our experiment, neither rosuvas-
tatin nor atorvastatin altered LCAT activity. In this study, rosu-
vastatin shifted the composition of HDL from mature HDL
to pre-β HDL without any changes in LCAT activity. In addi-
tion to LCAT, both hepatic lipase and endothelial lipase affect
the composition of HDL particles. Endothelial lipase expres-
sion resulted in the generation of small pre-β HDL particles
in wild-type mice.29 Hepatic lipase induced the formation of
pre-β1 HDL from triacylglycerol-rich HDL
2.30 If rosuvastatin
activates hepatic lipase and endothelial lipase, this activation
may change the composition of HDL and increase pre-β HDL.With regard to the lipid profile, such as the plasma levels
of LDL-C, HDL-C, and triglyceride, both rosuvastatin and
atorvastatin suppressed the increase in triglyceride levels after
a high-cholesterol diet, whereas a control group showed a
significant increase in triglyceride levels. In clinical studies,
statins have been shown to reduce not only LDL-C levels but
also triglyceride levels.13 Although we did not analyze lipo-
protein lipase activity, atorvastatin improved diabetic dyslip-
idemia and increased lipoprotein lipase activity in vivo while
reducing LDL-C, triglyceride, and very-low-density lipopro-
tein cholesterol.31
We also determined the mRNA expression of variousfactors in the liver. SR-BI receptor expressing a hepatocyte
3H-Plasma
0 20 40 60
1
10
100
rosuvastatin
atorvastatin
control
Time(hrs)
% C
P M i n j e c t e d
rosuvastatin atorvastatin control
0.0
0.1
0.2
0.3 FCR
F C R ( p o o l s / h r )
rosuvastatin atorvastatin control
0
10
20
30
Feces
% c
p m i
n j e c t e d
**
rosuvastatin atorvastatin control
0
5
10
15
20
25
3H-free cholesterol
% c
p m i
n j e c t e d
**
rosuvastatin atorvastatin control
0.0
0.5
1.0
1.5
2.0
2.5
3H-bile acids
% c p m i
n j e c t e d
A B
C D E
Figure 5. Effects of statins on the clearance of 3H-cholesteryl oleate–loaded high-density lipoprotein (HDL) in mice. C57BL6 (wild type)mice were fed a high-cholesterol diet for 2 weeks and then divided into 3 groups (5 each in the rosuvastatin and atorvastatin groups, 4 inthe placebo control group), which were orally administered their respective drugs for 6 weeks. HDL turnover studies were then performedas described in the Materials and Methods in the online-only Data Supplement. Decay curve of 3H-cholesteryl oleate-loaded HDL inplasma ( A ) and the plasma fractional catabolic rate (FCR; B ), 3H-cholesterol in feces ( C ), 3H-free cholesterol in feces ( D ), and 3H-bile acidin feces ( E ). CPM indicates counts per minute. *P
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
7/21
2252 Arterioscler Thromb Vasc Biol October 2014
cell surface is important for cholesterol transfer from HDL
to the liver.32 However, there was no significant difference
in SR-BI mRNA expression in this study. Statins did not
change macrophage SR-BI expression in mice or hepatic
SR-BI expression in dogs.27,33 Based on our HDL turnover
study, rosuvastatin may activate RCT without increasing
transport from HDL to the liver. Unexpectedly, rosuvas-
tatin decreased ApoA-I mRNA, although clinical studies
have shown an increase in ApoA-I levels.34–37 Marchesi
et al38 reported that rosuvastatin did not increase ApoA-I
transcription or hepatic secretion. The unexpected result
obtained in our study, that is, rosuvastatin reduced hepatic
ApoA-I mRNA, could be a consequence of hepatic choles-
terol depletion attributable to the inhibition of statin, which
may reduce hepatic HDL production.
Study LimitationsThere were several study limitations in this study. First,
there was a problem about optimal doses of rosuvastatin
and atorvastatin. We analyzed the mRNA levels of Cyp7A1,3-hydroxy-3-methylglutaryl coenzyme A reductase, and LDL
receptor (Figure III in the online-only Data Supplement). The
mRNA levels of 3-hydroxy-3-methylglutaryl coenzyme A
reductase in the atorvastatin group, but not the rosuvastatin
group, were significantly higher than those in the control
group. Although the dose of rosuvastatin in the present study
may not be optimal, rosuvastatin enhanced RCT in vivo. On
the contrary, although the dose of atorvastatin was optimal,
atorvastatin did not enhance RCT. We think that rosuvastatin
could enhance RCT, even though the dose was low. Second,
we did not analyze the hepatic levels of HDL-derived3H-cholesterol in Figure 5 because we used 3H-cholesteryl
oleate in the experiment, which is excreted into the fecesthrough bile without accumulating in the liver. Hence, we
used 3H-cholesterol ester which accumulates at a higher
rate in the liver 39 in an additional experiment. Although the
hepatic level of HDL-derived 3H-cholesteryl oleate in the
atorvastatin group was similar to that in the control group,
the level in the rosuvastatin group was significantly lower
than that in the atorvastatin group (data not shown). Thus,
the amount of cholesterol trapped in the liver decreased after
the administration of rosuvastatin. These results suggest that,
in the rosuvastatin group, cholesterol may pass through some
tissue or organ other than the liver. Further studies will be
needed to resolve this issue.
ConclusionsOur results indicate that rosuvastatin, but not atorvastatin,
promotes RCT in macrophage cells in vivo by activating
ABCA1-dependent efflux from peripheral macrophage cells
and increasing the excretion of cholesterol from the liver to
bile. The regression of atherosclerosis by rosuvastatin may
be more powerful than the effect of atorvastatin, and rosuvas-
tatin might be able to further reduce the incidence of cardio-
vascular events.
Acknowledgments
We thank Y. Matsuo and S. Abe for providing excellent technicalassistance.
DisclosuresK. Saku received research and education grants, consulting fees, andpromotional speaking fees from Pfizer Co Ltd. K. Saku is a ChiefDirector and S. Miura is a Director of NPO Clinical and AppliedScience, Fukuoka, Japan. K. Saku has an Endowed Department ofMolecular Cardiovascular Therapeutics supported by MSD, CoLtd and “Department of Advanced Therapeutics for CardiovascularDisease” supported by Boston Scientific Japan, Japan MedtronicInc, Japan Lifeline Co Ltd and St. Jude Medical Japan Co, Ltd.S. Miura and Y. Uehara belong to the Department of MolecularCardiovascular Therapeutics which is supported by MSD, Co Ltd.H. Tanigawa belongs to the Department of Advanced Therapeuticsfor Cardiovascular Disease supported by Boston Scientific Japan,Japan Medtronic Inc, Japan Lifeline Co Ltd and St. Jude MedicalJapan Co, Ltd. The other authors report no conflicts.
References 1. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R,
Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin
Evaluation and Infection Therapy-Thrombolysis in Myocardial
Infarction 22 Investigators. Intensive versus moderate lipid lowering
with statins after acute coronary syndromes. N Engl J Med . 2004;350:
1495–1504.
2. Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Amano A, Daida
H. The impact of pravastatin therapy on long-term outcome in patients
with metabolic syndrome undergoing complete coronary revasculariza-
tion. Circ J . 2009;73:2104–2109.
3. Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence
and treatment strategies. Am J Cardiol. 2005;96(9A):50K–58K; discus-
sion 34K.
4. Third report of the national cholesterol education program (NCEP)
expert panel on detection, evaluation, and treatment of high blood cho-
lesterol in adults (adult treatment panel III) final report. Circulation.
2002;106:3143–3421
5. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM,
Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators.
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular
events. N Engl J Med . 2007;357:1301–1310.
6. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Smith D, Weinberger
J, Wentzel J, Mizsei G, Mercuri M, Badimon JJ. Lipid lowering by sim-vastatin induces regression of human atherosclerotic lesions: two years’
follow-up by high-resolution noninvasive magnetic resonance imaging.
Circulation. 2002;106:2884–2887.
7. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, Chaplin WF,
Muntwyler J, Viles-Gonzalez JF, Weinberger J, Smith DA, Mizsei G,
Badimon JJ. Effects of aggressive versus conventional lipid-lowering
therapy by simvastatin on human atherosclerotic lesions: a prospective,
randomized, double-blind trial with high-resolution magnetic resonance
imaging. J Am Coll Cardiol. 2005;46:106–112.
8. Moreno PR, Sanz J, Fuster V. Promoting mechanisms of vascular health:
circulating progenitor cells, angiogenesis, and reverse cholesterol trans-
port. J Am Coll Cardiol. 2009;53:2315–2323.
9. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi
M, Ozaki Y, Kimura K, Saito S, Yamaguchi T, Daida H, Matsuzaki M;
JAPAN-ACS Investigators. Effect of intensive statin therapy on regression
of coronary atherosclerosis in patients with acute coronary syndrome: amulticenter randomized trial evaluated by volumetric intravascular ultra-
sound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assess-
ment of pitavastatin and atorvastatin in acute coronary syndrome] study).
J Am Coll Cardiol. 2009;54:293–302.
10. Schoenhagen P, Tuzcu EM, Apperson-Hansen C, Wang C, Wolski K,
Lin S, Sipahi I, Nicholls SJ, Magyar WA, Loyd A, Churchill T, Crowe T,
Nissen SE. Determinants of arterial wall remodeling during lipid-lowering
therapy: serial intravascular ultrasound observations from the Reversal of
Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL)
trial. Circulation. 2006;113:2826–2834.
11. Nozue T, Yamamoto S, Tohyama S, et al.; TRUTH Investigators.
Comparison of arterial remodeling and changes in plaque composition
between patients with progression versus regression of coronary athero-
sclerosis during statin therapy (from the TRUTH study). Am J Cardiol.
2012;109:1247–1253.
12. Nicholls SJ, Ballantyne CM, Barter PJ, Chapman MJ, Erbel RM, LibbyP, Raichlen JS, Uno K, Borgman M, Wolski K, Nissen SE. Effect of two
at BIREME / UNIFESP on February 26 2016http://atvb ahajournals org/Downloaded from
http://atvb.ahajournals.org/http://atvb.ahajournals.org/http://atvb.ahajournals.org/
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
8/21
Shimizu et al Rosuvastatin Promotes RCT 2253
intensive statin regimens on progression of coronary disease. N Engl J
Med . 2011;365:2078–2087.
13. Saku K, Zhang B, Noda K; PATROL Trial Investigators. Randomized
head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for
safety and efficacy (quantity and quality of LDL): the PATROL trial. Circ
J . 2011;75:1493–1505.
14. Kawano M, Nagasaka S, Yagyu H, Ishibashi S. Pitavastatin decreases
plasma prebeta1-HDL concentration and might promote its disap-
pearance rate in hypercholesterolemic patients. J Atheroscler Thromb.
2008;15:41–46.
15. Schaefer JR, Schweer H, Ikewaki K, Stracke H, Seyberth HJ, Kaffarnik H,
Maisch B, Steinmetz A. Metabolic basis of high density lipoproteins and
apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy
subjects and a patient with coronary artery disease. Atherosclerosis.
1999;144:177–184.
16. Asztalos BF, Horvath KV, McNamara JR, Roheim PS, Rubinstein JJ,
Schaefer EJ. Comparing the effects of five different statins on the HDL
subpopulation profiles of coronary heart disease patients. Atherosclerosis.
2002;164:361–369.
17. Zhang B, Kaneshi T, Ohta T, Saku K. Relation between insulin resistance
and fast-migrating LDL subfraction as characterized by capillary iso-
tachophoresis. J Lipid Res. 2005;46:2265–2277.
18. Zhang B, Miura S, Fan P, Kumagai K, Takeuchi K, Uehara Y, McMahon
M, Rye KA, Saku K. ApoA-I/phosphatidylcholine discs remodels fast-
migrating HDL into slow-migrating HDL as characterized by capillary
isotachophoresis. Atherosclerosis. 2006;188:95–101. 19. Schmitz G, Möllers C, Richter V. Analytical capillary isotachophoresis of
human serum lipoproteins. Electrophoresis. 1997;18:1807–1813.
20. Le May C, Berger JM, Lespine A, Pillot B, Prieur X, Letessier E, Hussain
MM, Collet X, Cariou B, Costet P. Transintestinal cholesterol excretion
is an active metabolic process modulated by PCSK9 and statin involving
ABCB1. Arterioscler Thromb Vasc Biol. 2013;33:1484–1493.
21. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K,
Sato R, Nagao T, Nishimaki-Mogami T. Sterol regulatory element-
binding protein-2- and liver X receptor-driven dual promoter regu-
lation of hepatic ABC transporter A1 gene expression: mechanism
underlying the unique response to cellular cholesterol status. J Biol Chem.
2007;282:21090–21099.
22. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman
AH, Posma JL, van Tol A, Kastelein JJ. Efficacy and safety of a novel cho-
lesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized
phase II dose-response study. Circulation. 2002;105:2159–2165. 23. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-
Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME,
Bamberger MJ. Raising high-density lipoprotein in humans through inhi-
bition of cholesteryl ester transfer protein: an initial multidose study of
torcetrapib. Arterioscler Thromb Vasc Biol. 2004;24:490–497.
24. Brousseau ME, Schaefer EJ, Wolfe ML, Bloedon LT, Digenio AG,
Clark RW, Mancuso JP, Rader DJ. Effects of an inhibitor of cholesteryl
ester transfer protein on HDL cholesterol. N Engl J Med . 2004;350:
1505–1515.
25. Glomset JA. The plasma lecithins:cholesterol acyltransferase reaction. J
Lipid Res. 1968;9:155–167.
26. Vaziri ND, Liang K. Effects of HMG-CoA reductase inhibition on
hepatic expression of key cholesterol-regulatory enzymes and receptors in
nephrotic syndrome. Am J Nephrol. 2004;24:606–613.
27. Song G, Liu J, Zhao Z, Yu Y, Tian H, Yao S, Li G, Qin S. Simvastatin
reduces atherogenesis and promotes the expression of hepatic genes asso-
ciated with reverse cholesterol transport in apoE-knockout mice fed high-
fat diet. Lipids Health Dis. 2011;10:8.
28. Bouzas L, San José E, Tutor JC. Chitotriosidase activity in pleural effu-
sions. Clin Lab. 2007;53:449–452.
29. Nijstad N, Wiersma H, Gautier T, van der Giet M, Maugeais C, Tietge
UJ. Scavenger receptor BI-mediated selective uptake is required for the
remodeling of high density lipoprotein by endothelial lipase. J Biol Chem.
2009;284:6093–6100.
30. Barrans A, Collet X, Barbaras R, Jaspard B, Manent J, Vieu C, Chap H,
Perret B. Hepatic lipase induces the formation of pre-beta 1 high den-
sity lipoprotein (HDL) from triacylglycerol-rich HDL2. A study com-
paring liver perfusion to in vitro incubation with lipases. J Biol Chem.
1994;269:11572–11577.
31. Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S,
Hamann A, Nawroth PP, Dugi KA. Atorvastatin improves diabetic dyslip-
idemia and increases lipoprotein lipase activity in vivo. Atherosclerosis.
2004;175:325–331.
32. Fidge NH. High density lipoprotein receptors, binding proteins, and
ligands. J Lipid Res. 1999;40:187–201.
33. Briand F, Magot T, Krempf M, Nguyen P, Ouguerram K. Effects of atorv-
astatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. Eur J Clin Invest . 2006;36:224–230.
34. Brown WV, Bays HE, Hassman DR, McKenney J, Chitra R, Hutchinson
H, Miller E; Rosuvastatin Study Group. Efficacy and safety of rosuvas-
tatin compared with pravastatin and simvastatin in patients with hyper-
cholesterolemia: a randomized, double-blind, 52-week trial. Am Heart J .
2002;144:1036–1043.
35. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP,
Suresh R, Sun S, Veltri EP. Ezetimibe coadministered with simvas-
tatin in patients with primary hypercholesterolemia. J Am Coll Cardiol.
2002;40:2125–2134.
36. Capuzzi DM, Morgan JM, Weiss RJ, Chitra RR, Hutchinson HG,
Cressman MD. Beneficial effects of rosuvastatin alone and in combina-
tion with extended-release niacin in patients with a combined hyperlip-
idemia and low high-density lipoprotein cholesterol levels. Am J Cardiol.
2003;91:1304–1310.
37. Hunninghake DB, Stein EA, Bays HE, Rader DJ, Chitra RR, SimonsonSG, Schneck DW. Rosuvastatin improves the atherogenic and atheropro-
tective lipid profiles in patients with hypertriglyceridemia. Coron Artery
Dis. 2004;15:115–123.
38. Marchesi M, Parolini C, Caligari S, Gilio D, Manzini S, Busnelli M, Cinquanta
P, Camera M, Brambilla M, Sirtori CR, Chiesa G. Rosuvastatin does not affect
human apolipoprotein A-I expression in genetically modified mice: a clue to
the disputed effect of statins on HDL. Br J Pharmacol. 2011;164:1460–1468.
39. Glass C, Pittman RC, Weinstein DB, Steinberg D. Dissociation of tissue
uptake of cholesterol ester from that of apoprotein A-I of rat plasma high
density lipoprotein: selective delivery of cholesterol ester to liver, adrenal,
and gonad. Proc Natl Acad Sci U S A. 1983;80:5435–5439.
Statin therapy reduces the incidence of cardiovascular events. It is controversial whether statins improve high-density lipoprotein (HDL)
function, which plays an important role in reverse cholesterol transport (RCT). We clarified the effects of rosuvastatin and atorvastatin on in
vivo macrophage RCT and the underlying mechanisms. Rosuvastatin, but not atorvastatin, increased macrophage-to-HDL RCT by activating
cholesterol efflux via ATP-binding cassette transporter A1. Furthermore, rosuvastatin increased liver-to-feces RCT by promoting the fecal
excretion of HDL-derived cholesterol. The differential effects of rosuvastatin and atorvastatin may be associated with the regression of
atherosclerosis. The regression induced by rosuvastatin may be more powerful than that induced by atorvastatin. Furthermore, cholesterol
ester transfer protein inhibitors markedly increase HDL cholesterol and decrease low-density lipoprotein cholesterol when administered in
combination with statins. Cholesterol ester transfer protein inhibitors combined with rosuvastatin may promote RCT via the induction of pre-β
HDL even if cholesterol ester transfer protein activity is blocked.
Significance
at BIREME / UNIFESP on February 26 2016http://atvb ahajournals org/Downloaded from
http://atvb.ahajournals.org/http://atvb.ahajournals.org/http://atvb.ahajournals.org/http://atvb.ahajournals.org/
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
9/21
Yoshinari Uehara and Keijiro SakuTomohiko Shimizu, Shin-ichiro Miura, Hiroyuki Tanigawa, Takashi Kuwano, Bo Zhang,
Diet High-Fatand Promotes Reverse Cholesterol Transport in Macrophage Cells in Mice Fed a
Dependent Efflux Ex Vivo−Rosuvastatin Activates ATP-Binding Cassette Transporter A1
Print ISSN: 1079-5642. Online ISSN: 1524-4636Copyright © 2014 American Heart Association, Inc. All rights reserved.
Greenville Avenue, Dallas, TX 75231is published by the American Heart Association, 7272 Arteriosclerosis, Thrombosis, and Vascular Biology
doi: 10.1161/ATVBAHA.114.3037152014;34:2246-2253; originally published online August 7, 2014; Arterioscler Thromb Vasc Biol.
http://atvb.ahajournals.org/content/34/10/2246
World Wide Web at:The online version of this article, along with updated information and services, is located on the
http://atvb.ahajournals.org/content/suppl/2014/08/07/ATVBAHA.114.303715.DC1.htmlData Supplement (unedited) at:
http://atvb.ahajournals.org//subscriptions/ at:
is online Arteriosclerosis, Thrombosis, and Vascular BiologyInformation about subscribing toSubscriptions: http://www.lww.com/reprints
Information about reprints can be found online at:Reprints:
document.Question and AnswerPermissions and Rightspage under Services. Further information about this process is available in the
which permission is being requested is located, click Request Permissions in the middle column of the WebCopyright Clearance Center, not the Editorial Office. Once the online version of the published article for
can be obtained via RightsLink, a service of the Arteriosclerosis, Thrombosis, and Vascular Biologyin Requests for permissions to reproduce figures, tables, or portions of articles originally publishedPermissions:
at BIREME / UNIFESP on February 26 2016http://atvb ahajournals org/Downloaded from
http://atvb.ahajournals.org/content/34/10/2246http://atvb.ahajournals.org/content/suppl/2014/08/07/ATVBAHA.114.303715.DC1.htmlhttp://atvb.ahajournals.org/content/suppl/2014/08/07/ATVBAHA.114.303715.DC1.htmlhttp://atvb.ahajournals.org/content/suppl/2014/08/07/ATVBAHA.114.303715.DC1.htmlhttp://atvb.ahajournals.org//subscriptions/http://atvb.ahajournals.org//subscriptions/http://www.lww.com/reprintshttp://www.lww.com/reprintshttp://www.lww.com/reprintshttp://www.ahajournals.org/site/rights/http://www.ahajournals.org/site/rights/http://www.ahajournals.org/site/rights/http://www.ahajournals.org/site/rights/http://atvb.ahajournals.org/http://atvb.ahajournals.org/http://atvb.ahajournals.org/http://atvb.ahajournals.org/http://atvb.ahajournals.org//subscriptions/http://www.lww.com/reprintshttp://www.ahajournals.org/site/rights/http://www.ahajournals.org/site/rights/http://atvb.ahajournals.org/content/suppl/2014/08/07/ATVBAHA.114.303715.DC1.htmlhttp://atvb.ahajournals.org/content/34/10/2246
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
10/21
1
Supplement
Materials and Methods
Materials
The following antibodies and reagents were purchased or provided: Dulbecco modified
Eagle medium (DMEM) and phosphate buffer saline (PBS) (Wako Pure Chemical
Industries Ltd., Osaka, Japan); [1,2-3H]cholesterol, [1,2-3H]cholesteryl oleate (Perkin
Elmer Life & Analytical Sciences Inc.); rosuvastatin and atorvastatin (Toronto Research
Chemicals, Inc., Canada); 8-(4-chlorophenylthio)adenosine 3',5'-cyclic monophosphate
(8-CTP-cAMP) (Enzo Life Sciences, Inc., New York, NY); human HDL (Calbiochem,
Darmstadt, Germany); and the liver X receptor (LXR) agonist T0-901317 and the
retinoid X receptor (RXR) agonist 9-cis-retinoic acid (Sigma-Aldrich, St. Louis, MO).
Mice, Diets and Experimental Design
Wild-type (WT) C57BL/6J mice were purchased from Japan SLC Inc. (Shizuoka,
Japan). Mice were housed in specific pathogen-free barrier facilities at Fukuoka
University. Mice were maintained under a 12-h light/dark cycle and fed a 0.5 %
high-cholesterol diet + 10 % coconut oil (purchased from Oriental Yeast Co. Ltd.,
Tokyo, Japan) (Content of diet were shown in Supplementary Table I), which was
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
11/21
2
provided ad libitum for 2 weeks before and during the study. In all cases, fasting
plasma was obtained from the retro-orbital plexus while the mice were under isoflurane
anesthesia. For each experiment, female 3- to 4-month-old C57BL/6 mice were
divided into 3 groups; 4 mg/kg/day rosuvastatin (rosuvastatin group), 8 mg/kg/day
atorvastatin (atorvastatin group) and 0.5 % methylcellulose (control group) dissolved in
freely available drinking water for 6 weeks. In a study by de Haan et al., mice
received diet with or without 0.01% (w/w) atorvastatin for 6 weeks (i.e., approximately
10 mg/kg/day, which corresponds to a dose of 70 mg/day for an average 70 kg person)
[1]. Since the maximum doses of rosuvastatin and atorvastatin in humans are 40 mg/day
and 80 mg/day, respectively, the doses of rosuvastatin and atorvastatin in mice were
determined to be 4 mg/kg/day and 8 mg/kg/day, respectively. Animal experiments
were approved by the Fukuoka University Animal Center Committee.
Plasma Lipid, Lipoprotein and lecithin-cholesterol acyltransferase (LCAT)
Activity Analyses
Plasma total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C), triglycerides (TG) and LCAT activities were measured
by a commercial kit (Sekisui Medical Co. Ltd., Japan). Lipoprotein subfractions in
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
12/21
3
serum and serum fractions were analyzed by capillary isotachophoresis (cITP) on a
Beckman P/ACE MDQ system (Beckman-Coulter, Tokyo, Japan) as described
previously [2]. cITP is a technique for analyzing charge-based lipoprotein subfractions
directly in plasma [3, 4]. cITP can separate plasma lipoproteins into three HDL
subfractions [fast- (f), intermediate- (i), and slow- (s) migrating HDL] according to their
electrophoretic mobilities. The levels of cITP HDL subfractions can be determined as
peak areas relative to that of an internal marker.
RNA Quantification
Total RNA was isolated from mouse primary hepatocytes with an RNeasy Mini Kit
(QIAGEN, Hilden, Germany). cDNA was produced from total RNA via reverse
transcription with a SuperScript First-Stand Synthesis System for RT-PCR (Life
Technologies, Grand Island, NY). mRNA expression with Taqman assay systems was
quantified by an ABI 7500 Real Time PCR System according to the manufacturer’s
instructions (Life Technologies, Grand Island, NY) for scavenger receptor class B type I
(SR-BI), ATP-binding cassette transporter (ABC) A1, liver X receptor (LXR), farnesoid
X receptor (FXR), apolipoprotein (Apo)A-1, ABCG8, ABCG5, sterol regulatory
element-binding protein 2 (SREBP-2) and -actin RNA. The expression data were
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
13/21
4
normalized for -actin levels.
Ex Vivo Cholesterol Efflux from Bone Marrow Macrophage and J774 Macrophage
Cells
Plasma samples were collected from mice after 6 weeks of treatment. Plasma HDL
(apoB-depleted plasma)-mediated cholesterol efflux was measured in cAMP-treated
J774 macrophage cells as described above. For the preparation of apoB-depleted
plasma, plasma was mixed in a tube containing the precipitation reagent (0.55 mmol/l
phosphotungstic acid and 25 mmol/l magnesium chloride). After 10 min at room
temperature, this mixture was centrifuged for 10 min at 3,000g. The clear supernatant
was separated and stored in capped glass tubes for a maximum of 2 days at 4°C before
the cholesterol content was determined by the cholesterol oxidase/ p-aminophenazone
method. We measured plasma HDL-C-mediated efflux in bone marrow macrophage
(BMM) with or without probucol, which specifically inhibits ABCA1. J774
macrophages were plated in 12-well plates (0.25×106 /mL) in DMEM with 10 % fetal
bovine serum (FBS) and 0.5 % penicillin G and streptomycin at 37 °C. After 1 day,
the cells were labeled for 24 h at 37 °C with 3 μCi/mL [1,2-3H]cholesterol and 50
μg/mL acetylated low-density cholesterol (ac-LDL) in the presence of 1.0 % FBS and
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
14/21
5
0.5 % penicillin G and streptomycin in DMEM. Cells were washed extensively with
PBS with 1.0 % bovine serum albumin (BSA), and J774 macrophages were then
equilibrated with or without 0.3 mmol/L cAMP, which activates mainly ABCA1, in 0.2
% BSA-containing medium for 20 h at 37 °C [5]. At the end of the equilibration
period, cell monolayers were washed twice with PBS containing 1 % BSA.
Subsequently, cholesterol efflux was induced by incubation for 4 h at 37°C with each
pooled plasma (excluding apo-B-containing protein) diluted to 2 % in DMEM. Free
cholesterol efflux was obtained by measuring the release of radiolabeled cholesterol into
the medium as described previously [6].
Next, BMM were isolated from mice by standard procedures [7]. Isolated
macrophages were suspended and cultured in 12-well plates (0.25×106 /mL) in DMEM
with 10 % FBS plus 0.5 % penicillin G and streptomycin at 37°C. After 4 days,
macrophages were labeled for 24 h at 37°C with 2 μCi/mL [1, 2-3H]cholesterol and 25
μg/mL ac-LDL in the presence of 1.0 % FBS and 0.5 % penicillin G and streptomycin
in DMEM. BMM were washed extensively with PBS with 1 % BSA and equilibrated
overnight in the presence of the LXR agonist T0-901317 and the RXR agonist 9-cis
(each 5 μM) in serum-free medium. For cholesterol efflux, BMM were treated with or
without 20 μM probucol for 2 h at 37°C [8]. After 4 h, aliquots of the medium were
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
15/21
6
removed, and the 3H-cholesterol released was measured by liquid scintillation counting.
The 3H-cholesterol present in the cells was determined by extracting cell lipids in 0.2 M
NaOH and 0.15 M NaCl.
Macrophage reverse cholesterol transport (RCT) Study
The RCT study was performed as described previously [9-11]. J774 macrophages
were grown in DMEM supplemented with 10 % FBS. The cells were radiolabeled
with 5 μCi/mL 3H-cholesterol and cholesterol enriched with 25 μg/mL ac-LDL for 40 h.
The labeled foam cells were washed, equilibrated in medium with 0.2 % bovine serum
albumin for 4 hours, spun down and resuspended in DMEM immediately before use.
All mice were fed a 0.5 % high-cholesterol diet for 2 weeks before experiments as
prefeeding. For this experiment, 21 female 3- to 4-month-old mice (n=7/each group)
were divided into 3 groups (rosuvastatin, atorvastatin and control groups). After 6
weeks, 3H-cholesterol-labeled and acetylated LDL-C-loaded J774 cells were injected
intraperitoneally. Blood was collected at 6, 24 and 48 h, and plasma samples were
used for liquid scintillation counting. Feces were collected continuously from 0 to 48
h and stored at 4 °C before the extraction of cholesterol and bile acid.
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
16/21
7
HDL Turnover Study
Human HDL was labeled with 3H-cholesteryl oleate as described previously with slight
modifications [11, 12]. For the experiment, 15 female 3- to 4-month-old mice
(n=5/each group) were divided into 3 groups (rosuvastatin, atorvastatin and control
groups). After 6 weeks, labeled HDL was injected intravenously. Blood was
collected at 2 min and 1, 3, 6, 9, 24 and 48 h, and liver and feces were collected at 48 h.
The fractional catabolic rate (FCR) was calculated using the SAS (Statistical Analysis
System) software package (Ver. 9.2; SAS Institute Inc., Cary, NC) as described
previously [12, 13].
Statistical Analysis
The results before and after drug administration were compared with the Student t test
(2-tailed) and analysis of variance (ANOVA) using GraphPad Prism version 5.0
(GraphPad Software Inc., La Jolla, CA). For the macrophage RCT studies, the
appearance of tracer in plasma was analyzed by repeated measures ANOVA, and a
Newman-Keuls multiple comparison test was applied to correct for multiple
comparisons. One-way ANOVA with a Newman-Keuls multiple comparison test was
used to compare the differences among the 3 groups. All data are presented as the
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
17/21
8
mean ± standard deviation (SD). A probability value
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
18/21
9
cellular cholesterol efflux to lipid-free apolipoprotein A-I by camp. Biochim
Biophys Acta. 1999;1438:85-98
6. Rothblat GH, de la Llera-Moya M, Favari E, Yancey PG, Kellner-Weibel G.
Cellular cholesterol flux studies: Methodological considerations. Atherosclerosis.
2002;163:1-8
7. Yona S, Heinsbroek SE, Peiser L, Gordon S, Perretti M, Flower RJ. Impaired
phagocytic mechanism in annexin 1 null macrophages. Br J Pharmacol.
2006;148:469-477
8. Favari E, Zanotti I, Zimetti F, Ronda N, Bernini F, Rothblat GH. Probucol
inhibits abca1-mediated cellular lipid efflux. Arterioscler Thromb Vasc Biol.
2004;24:2345-2350
9. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic
expression of scavenger receptor class b type I (SR-BI) is a positive regulator of
macrophage reverse cholesterol transport in vivo. J Clin Invest.
2005;115:2870-2874
10. Tanigawa H, Billheimer JT, Tohyama J, Zhang Y, Rothblat G, Rader DJ.
Expression of cholesteryl ester transfer protein in mice promotes macrophage
reverse cholesterol transport. Circulation. 2007;116:1267-1273
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
19/21
10
11. Alexander ET, Weibel GL, Joshi MR, Vedhachalam C, de la Llera-Moya M,
Rothblat GH, Phillips MC, Rader DJ. Macrophage reverse cholesterol transport
in mice expressing apoa-i milano. Arterioscler Thromb Vasc Biol.
2009;29:1496-1501
12. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, Rader DJ.
Overexpression of secretory phospholipase a(2) causes rapid catabolism and
altered tissue uptake of high density lipoprotein cholesteryl ester and
apolipoprotein A-I. J Biol Chem. 2000;275:10077-10084
13. Maugeais C, Tietge UJ, Broedl UC, Marchadier D, Cain W, McCoy MG,
Lund-Katz S, Glick JM, Rader DJ. Dose-dependent acceleration of high-density
lipoprotein catabolism by endothelial lipase. Circulation. 2003;108:2121-2126
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
20/21
Supplementary Figs and Tables.
Supplementary Table I. Content of diet.
Crude protein 20.7g/100g diet
Crude fat 15.1g/100g
Crude ash 5.2g/100g
Crude fiber 2.5g/100g
Nitrogen free extract 49.5g/100g
Water 7.1g/100g
Supplemental Figure I. mRNA levels of ABCG5, ABCB1a, NPC1L1 and LDL receptor
in the intestine in the rosuvastatin, atorvastatin and control groups.
Supplemental Figure II. Intestinal absorption of cholesterol in the rosuvastatin,
atorvastatin and control groups.
rosuvastatin atorvastatin control0
10
20
30
Feces
% c
p m i n j e c t e d
**
Methods for measurement of the intestinal absorption of cholesterol
Wild-type mice were divided into 3 groups; 4 mg/kg/day rosuvastatin (rosuvastatin
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
NPC1L1 mRNA express ion
(AU)
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
ABCB1a mRNA expr ess ion
(AU)
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
2.0
2.5
LDL-R mRNA expressi on
(AU)
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
ABCG5 mRNA exp ressio n
(AU)
8/17/2019 Arterioscler Thromb Vasc Biol 2014 Shimizu 2246 53
21/21
group, n=7), 8 mg/kg/day atorvastatin (atorvastatin group, n=8) and 0.5 %
methylcellulose dissolved in water (control group, n= 8) for 2 weeks. We measured
intestinal cholesterol absorption function by a fecal dual-isotope ratio method, as
described previously [1, 2].
Briefly, mice were gavaged with 150 μl of safflower oil (195-15372, Wako Pure
Chemical Industries, Ltd. Japan) that contained a mixture of 2 μCi [5,6-3H] sitostanol
(ART 0361, American Radiolabeled Chemicals Inc., St. Louis, MO, USA) and 1 μCi
[4-14C] cholesterol (NEC018250UC, PerkinElmer Life Sciences, USA), and then
returned to fresh cages. Feces were collected from individually housed mice in
wire-bottom cages after the administration of label and processed as described
previously following homogenization and neutral sterol extraction of fecal samples. The
ratio of 14C and 3H sterol in each feces sample and the dosing mixture were determined
by liquid scintillation counting and the cholesterol absorption percentage was calculatedas described previously [2, 3].
References:
1. Xie Y, Newberry EP, Young SG, Robine S, Hamilton RL, Wong JS, Luo J, Kennedy
S, Davidson NO. Compensatory increase in hepatic lipogenesis in mice with
conditional intestine-specific mttp deficiency. J Biol Chem. 2006;281:4075-4086.
2. Wang DQ, Carey MC. Measurement of intestinal cholesterol absorption by plasma
and fecal dual-isotope ratio, mass balance, and lymph fistula methods in the mouse:
an analysis of direct versus indirect methodologies. J Lipid Res.
2003;44:1042-1059.
3. Newberry EP, Xie Y, Kennedy SM, Luo J, Davidson NO. Protection against Western
diet-induced obesity and hepatic steatosis in liver fatty acid-binding protein
knockout mice. Hepatology. 2006;44:1191-1205.
Supplemental Figure III. mRNA levels of Cyp7A1, HMG-CoA reductase and LDL-R in
the liver in the rosuvastatin, atorvastatin and control groups.
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
Cyp7A1 mRNA expression
(AU)
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
2.0
HMG-CoA reductase mRNA expression
(AU)
* *
rosuvastatin atorvastatin control0.0
0.5
1.0
1.5
LDL-R mRNA express ion
(AU)